Zobrazeno 1 - 10 of 93 pro vyhledávání: '"Richard A Alm"'
1
Akademický článek
A novel pre-clinical antibacterial pipeline database.
Autor: Sarah Paulin, Richard A Alm, Peter Beyer
Publikováno v: PLoS ONE, Vol 15, Iss 7, p e0236604 (2020)
The clinical pipeline continues to be insufficient to contain antimicrobial resistance, and further investment and research is needed to ensure that a robust pipeline is built to treat the WHO priority pathogens list of antibiotic-resistant bacteria.
Externí odkaz: https://doaj.org/article/7e5fc0589a8e435e84d2751950f88f0f
Zobrazit plný text záznamu
2
The CARB-X Portfolio of Nontraditional Antibacterial Products
Autor: Erin M. Duffy, Nadia R. Cohen, Su L. Chiang, Ed T. Buurman, Maria Uria-Nickelsen, Richard A. Alm
Publikováno v: ACS Infectious Diseases. 7:2043-2049
The growing prevalence of antibiotic-resistant bacterial pathogens and the lack of new medicines to treat the infections they cause remain a significant global threat. In recent years, this ongoing unmet need has encouraged more research groups to fo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::495d91af336e507954cc87812d30b5ef
https://doi.org/10.1021/acsinfecdis.1c00331
Zobrazit plný text záznamu
5
Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed
Autor: Mark S. Butler, Valeria Gigante, Hatim Sati, Sarah Paulin, Laila Al-Sulaiman, John H. Rex, Prabhavathi Fernandes, Cesar A. Arias, Mical Paul, Guy E. Thwaites, Lloyd Czaplewski, Richard A. Alm, Christian Lienhardt, Melvin Spigelman, Lynn L. Silver, Norio Ohmagari, Roman Kozlov, Stephan Harbarth, Peter Beyer
Publikováno v: Antimicrob Agents Chemother
There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critica
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76943be92776f3f4b8f59eb45535c2de
https://doi.org/10.1128/aac.01991-21
Zobrazit plný text záznamu
6
Innovation in Antimicrobial Resistance: The CARB-X Perspective
Autor: Karen Gallant, Richard A. Alm
Publikováno v: ACS Infectious Diseases. 6:1317-1322
The spread of drug-resistant bacterial pathogens has been recognized as one of the largest global threats to mankind. In order to continue to benefit from the advancement of modern medicine, new treatments, prevention, and diagnostic products are nee
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::872e1f7c37be91dafc5123fea8152cdc
https://doi.org/10.1021/acsinfecdis.0c00026
Zobrazit plný text záznamu
8
A novel pre-clinical antibacterial pipeline database
Autor: Richard A. Alm, Peter Beyer, Sarah Paulin
Publikováno v: PLoS ONE
PLoS ONE, Vol 15, Iss 7, p e0236604 (2020)
The clinical pipeline continues to be insufficient to contain antimicrobial resistance, and further investment and research is needed to ensure that a robust pipeline is built to treat the WHO priority pathogens list of antibiotic-resistant bacteria.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393bbba7a0ebec58187ffc6bcbc586fe
http://europepmc.org/articles/PMC7386594
Zobrazit plný text záznamu
9
Narrow-Spectrum Antibacterial Agents—Benefits and Challenges
Autor: Sushmita D. Lahiri, Richard A. Alm
Publikováno v: Antibiotics
Antibiotics, Vol 9, Iss 418, p 418 (2020)
The number of antibacterial agents in clinical and preclinical development possessing activity against a narrow spectrum of bacterial pathogens is increasing, with many of them being nontraditional products. The key value proposition hinges on sparin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::773c5732ae2eca3642afcab48402a305
http://europepmc.org/articles/PMC7400354
Zobrazit plný text záznamu
10
A one health framework to estimate the cost of antimicrobial resistance
Autor: GM Bruno, Elena Carrara, Marc Mendelson, Souha S. Kanj, Luca Guardabassi, Malgorzata Mikulska, Richard A. Alm, Finola C. Leonard, Evelina Tacconelli, Nico T. Mutters, Sabiha Y. Essack, Jesus Rodriguez Baňo, Kevin Outterson, Tomislav Kostyanev, Herman Goossens, Alessandra Bandera, Peter Søgaard Jørgensen, Giorgio Colombo, Chantal M. Morel, Ramanan Laxminarayan, Stéphan Juergen Harbarth, Bruno Gonzalez-Zorn, Isabel Frost, Christine Årdal, Marlieke E. A. de Kraker, Luigia Scudeller, Gabriel Levy Hara
Publikováno v: Morel, C M, Alm, R A, Årdal, C, Bandera, A, Bruno, G M, Carrara, E, Colombo, G L, de Kraker, M E A, Essack, S, Frost, I, Gonzalez-Zorn, B, Goossens, H, Guardabassi, L, Harbarth, S, Jørgensen, P S, Kanj, S S, Kostyanev, T, Laxminarayan, R, Leonard, F, Hara, G L, Mendelson, M, Mikulska, M, Mutters, N T, Outterson, K, Baňo, J R, Tacconelli, E, Scudeller, L & the GAP-ON€ network 2020, ' A one health framework to estimate the cost of antimicrobial resistance ', Antimicrobial Resistance and Infection Control, vol. 9, no. 1, 187 . https://doi.org/10.1186/s13756-020-00822-6
Antimicrobial resistance & infection control
Antimicrobial Resistance and Infection Control, Vol 9, Iss 1, Pp 1-14 (2020)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Antimicrobial Resistance and Infection Control
[Objectives/purpose] The costs attributable to antimicrobial resistance (AMR) remain theoretical and largely unspecified. Current figures fail to capture the full health and economic burden caused by AMR across human, animal, and environmental health
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad1a768f935c567adde3977fea3043d
https://curis.ku.dk/portal/da/publications/a-one-health-framework-to-estimate-the-cost-of-antimicrobial-resistance(1d594386-4f88-43a3-bcaa-0bbb71f6517a).html
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje